IO Biotech's price target raised to $14 from $12, with lower operating expenses

From Yahoo Finance: 2025-05-15 12:11:00

H.C. Wainwright raised IO Biotech’s price target to $14 from $12, keeping a Buy rating post Q1 report. Lower operating expenses led to the target increase. Phase 3 advanced melanoma data is on track for Q3. TheFly is a real-time source for market-moving financial news. See top stocks recommended by analysts.



Read more at Yahoo Finance: IO Biotech price target raised to $14 from $12 at H.C. Wainwright